| Assay ID | Title | Year | Journal | Article |
|---|
| AID309933 | Inhibition of aldose reductase | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
| Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. |
| AID367705 | Inhibition of human recombinant ALR2 expressed in bacterial cell expression system | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
| Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. |
| AID176722 | Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 4 days in lens | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID322413 | Inhibition of human recombinant aldose reductase | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
| Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors. |
| AID185751 | Percentage Inhibition of galactitol accumulation in the lens of rats fed with the dose of 4.0 mg/kg/day; NS=Not significant | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID35130 | Compound was evaluated In vitro for inhibition of aldose reductase activity by 50% in rat RBC | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID367709 | Inhibition of pig ALR1 by mixed inhibition based Lineweaver-Burke plot | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
| Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. |
| AID322409 | Inhibition of mouse recombinant AKR1C21 | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
| Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors. |
| AID176721 | Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 14 days in sciatic nerve | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID185752 | Percentage Inhibition of galactitol accumulation in the sciatic nerve of rats fed with the dose of 0.5 mg/kg/day | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID176719 | Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 14 days in RBC | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID176723 | Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 4 days in sciatic nerve | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID34627 | Compound was evaluated In vitro for inhibition of aldose reductase activity by 50% in dog RBC | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID489639 | Inhibition of N-terminal 6His-tagged human aldehyde reductase expressed in Escherichia coli BL21(DE3) mediated D-glucuronate reduction | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. |
| AID185760 | Percentage Inhibition of galactitol accumulation in the sciatic nerve of rats fed with the dose of 1.1 mg/kg/day | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID34205 | In vitro inhibition of aldose reductase activity in a partially purified bovine lens preparation | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID19449 | Log P value by using Octanol / pH 7.4 buffer | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID367706 | Selectivity ratio of IC50 for human recombinant ALR2 to IC50 for pig ALR1 | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
| Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. |
| AID176720 | Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 14 days in lens | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID489641 | Selectivity ratio of IC50 for human ALR to IC50 for AKR1B10 | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. |
| AID489642 | Selectivity ratio of IC50 for human ALR to IC50 for human AR | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. |
| AID489640 | Selectivity ratio of IC50 for human AR to IC50 for AKR1B10 | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. |
| AID367703 | Inhibition of human recombinant ALR2 expressed in bacterial cell expression system by Uncompetitive inhibition based Lineweaver-Burke plot | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
| Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. |
| AID367704 | Inhibition of pig ALR1 | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
| Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. |
| AID489631 | Inhibition of reductase activity of N-terminal 6His-tagged AKR1B10 expressed in Escherichia coli BL21(DE3) assessed as inhibition of NADPH linked pyridine-3-aldehyde reduction | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. |
| AID185747 | Percentage Inhibition of galactitol accumulation in the lens of rats fed with the dose of 1.1 mg/kg/day; NS=Not significant | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID185765 | Percentage Inhibition of galactitol accumulation in the sciatic nerve of rats fed with the dose of 4.0 mg/kg/day | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
| Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. |
| AID489638 | Inhibition of N-terminal 6His-tagged human aldose reductase expressed in Escherichia coli BL21(DE3) mediated NADPH linked pyridine-3-aldehyde reduction | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. |
| AID1802839 | SPR Assay from Article 10.1021/acschembio.7b00062: \\Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.\\ | 2017 | ACS chemical biology, 05-19, Volume: 12, Issue:5
| Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |